HIV/AIDS
Conditions
Keywords
HIV prevention, high risk MSM, sero-discordant couples, PrEP
Brief summary
75 subjects at risk for HIV infection (25 high risk MSM and 50 sero-discordant couples) will be recruited. All subjects will receive Truvada for pre-exposure prophylaxis or PrEP, as well as routine medical evaluations during one year. Subjects will be managed according to CDC's guidelines on the management of PrEP as a tool for HIV prevention.
Detailed description
75 subjects at risk for HIV infection (25 high risk MSM and 50 sero-discordant couples) will be recruited. All subjects will receive Truvada for PrEP, as well as routine medical evaluations during one year. Subjects will be managed according to CDC's guidelines on the management of PrEP as a tool for HIV prevention. All subjects will have a total of at least 8 study visits during which routine assessment are performed for patients on Truvada for PrEP. Apart from offering routine medical care, a baseline questionnaire that includes socio-demographic variables, PrEP knowledge and acceptability and sexual conducts will be offered. At the 6 months visit, an abbreviated sexual conducts questionnaire will be offered.
Interventions
DRUGEmtricitabine and Tenofovir
All subjects will be provided study drug for use daily for one year.
Sponsors
Gilead Sciences
Puerto Rico Community Network for Clinical Research on AIDS
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
All subjects will receive same treatment with study drug
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Subject is a male, female or transgender female age 21 or older 2. Subject provides written informed consent. 3. Subject provides written authorization for use and disclosure of protected health information (PHI). 4. Subject has one of the following risk factors: * male, female or transgender female or female sexual partner of an HIV-infected individual, ideally who is not virologically suppressed * high risk MSM as defined by: having unprotected sexual intercourse with at least two male partner in the last 6 months, or * diagnosed with an STI in the past 6 months 5. Baseline eCrCl of ≥60 ml/min (calculated using the CKD-EPI formula) 6. Negative Hepatitis B serology 7. No medical contraindications to the use of PrEP 8. Confirmed HIV negative by 5th generation (AB/antigen) HIV test
Exclusion criteria
1. younger than 21 years of age 2. unable to provide consent 3. Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice). 4. Positive pregnancy test: Women of childbearing potential must have a negative serum or urine pregnancy test within 1 week prior to study entry. Pregnancy testing will also be performed in enrolled female participants prior to any study procedures being performed 5. Baseline eCrCl \<60 ml/min 6. Positive Hepatitis B serology to avoid potential flares upon product discontinuation 7. Any medical contraindication to the use of PrEP or any other conditions deemed by the study investigator to exclude the subject's participation in the study 8. HIV infected 9. Signs and symptoms of acute HIV infection 10. For sero-discordant couples: upon review of HIV positive partner's chart, evidence of resistance to any of the components of the study drug. 11. Illness or other condition that, in the opinion of the PI, may interfere with study participation at the time of enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Retention in care | 12 months | Retention to follow up clinical visits based on completed and missed visits |
| Treatment adherence | 12 months | Determine adherence to study drug based on pill count and died blood spots (DBS) |
| PrEP knowledge | 12 months | Measure the level of education of the study subjects in the topic of PrEP using a questionnaire |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Study drug safety | 12 months | Determine safety of study drug based on AE reports related to treatment |
| HIV sero-prevalence | 12 months | Determine the sero-prevalence of the study subjects receiving PrEP based on the number of study subjects diagnosed with HIV during study duration. |
| Changes in sexual risk behaviors | 12 months | Measure changes from baseline sexual risk behaviors after initiating use of study drug, specifically frequency of unprotected sexual intercourse according to sexual behaviors questionnaire. |
Countries
Puerto Rico
Outcome results
None listed